Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension.

Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research16 Feb 2021Cited by 23 (Europe PMC)

PMID33507574DOI10.1002/jbmr.4259PepBankPUB-33507574

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In postmenopausal women, zoledronic acid maintained femoral neck BMD gains after combined teriparatide and denosumab.
In plain wordsIn postmenopausal women, zoledronic acid maintained femoral neck bone density gains after combined teriparatide and denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD maintenance
Study
n = 53
Outcome group
Bone and joint · Musculoskeletal
Measurements
Initial femoral neck BMD gain
5.6%
months 0 to 15
Source sentences
Summary
At the femoral neck and total hip, the mean 5.6% and 5.1% gains in BMD achieved from month 0 to 15 were maintained both 12 and 27 months after zoledronic acid administration.
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a preplanned extension of the DATA-HD study, where postmenopausal women with osteoporosis were randomized to receive 9 months of either 20 μg or 40 μg of teriparatide daily overlapping with denosumab (60 mg administered at months 3 and 9).
Summary · context
At the completion of this 15-month study, women were invited to enroll in the DATA-HD Extension where they received a single dose of zoledronic acid (5 mg) 24 to 35 weeks after the last denosumab dose.
Summary · context
Fifty-three women enrolled in the DATA-HD Extension.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3350757401
02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In postmenopausal women, zoledronic acid maintained total hip BMD gains after combined teriparatide and denosumab.
In plain wordsIn postmenopausal women, zoledronic acid maintained hip bone density gains after combined teriparatide and denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD maintenance
Study
n = 53
Outcome group
Bone and joint · Musculoskeletal
Measurements
Initial total hip BMD gain
5.1%
months 0 to 15
Source sentences
Summary
At the femoral neck and total hip, the mean 5.6% and 5.1% gains in BMD achieved from month 0 to 15 were maintained both 12 and 27 months after zoledronic acid administration.
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a preplanned extension of the DATA-HD study, where postmenopausal women with osteoporosis were randomized to receive 9 months of either 20 μg or 40 μg of teriparatide daily overlapping with denosumab (60 mg administered at months 3 and 9).
Summary · context
At the completion of this 15-month study, women were invited to enroll in the DATA-HD Extension where they received a single dose of zoledronic acid (5 mg) 24 to 35 weeks after the last denosumab dose.
Summary · context
Fifty-three women enrolled in the DATA-HD Extension.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3350757402
03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In postmenopausal women, spine BMD after combined teriparatide and denosumab remained stable initially but declined later after zoledronic acid.
In plain wordsIn postmenopausal women, spine bone density remained stable initially but declined later after zoledronic acid following combined teriparatide and denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedSpine BMD maintenance
Study
n = 53
Outcome group
Bone and joint · Musculoskeletal
Measurements
Initial spine BMD gain
13.6%
months 0 to 15
Spine BMD reduction
3%
27 months after zoledronic acid
Spine BMD reduction 95% CI
−4 to −2%
27 months after zoledronic acid
Source sentences
Summary
At the spine, the mean 13.6% gain in BMD achieved from month 0 to 15 was maintained for the first 12 months but modestly decreased thereafter, resulting in a 3.0% reduction (95% CI, -4.0% to -2.0%, p < .0001) 27 months after zoledronic acid.
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a preplanned extension of the DATA-HD study, where postmenopausal women with osteoporosis were randomized to receive 9 months of either 20 μg or 40 μg of teriparatide daily overlapping with denosumab (60 mg administered at months 3 and 9).
Summary · context
At the completion of this 15-month study, women were invited to enroll in the DATA-HD Extension where they received a single dose of zoledronic acid (5 mg) 24 to 35 weeks after the last denosumab dose.
Summary · context
Fifty-three women enrolled in the DATA-HD Extension.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3350757403
04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In postmenopausal women after combined treatment, BMD change patterns after zoledronic acid were qualitatively similar across prior teriparatide dose groups.
In plain wordsIn postmenopausal women after combined treatment, bone density change patterns after zoledronic acid were qualitatively similar across prior teriparatide dose groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBMD change pattern by prior dose
Study
n = 53
Comparator
Prior 20-μg teriparatide group
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The pattern of BMD changes between months 15 and 42 were qualitatively similar in the 20-μg and 40-μg groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This study is a preplanned extension of the DATA-HD study, where postmenopausal women with osteoporosis were randomized to receive 9 months of either 20 μg or 40 μg of teriparatide daily overlapping with denosumab (60 mg administered at months 3 and 9).
Summary · context
At the completion of this 15-month study, women were invited to enroll in the DATA-HD Extension where they received a single dose of zoledronic acid (5 mg) 24 to 35 weeks after the last denosumab dose.
Summary · context
Fifty-three women enrolled in the DATA-HD Extension.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3350757404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.